Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Prempro second-line use

Executive Summary

FDA's Endocrinologic & Metabolic Drugs Advisory Committee will discuss Women's Health Initiative study results and limiting estrogen/progestin products (Wyeth's Prempro and others) to second-line use for prevention and treatment of osteoporosis on Oct. 7. The WHI study found increased breast cancer and cardiovascular risks with Prempro use (1"The Pink Sheet" July 28, 2003, p. 35). The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8 a.m. [To 2watch a webcast or video of this meeting, go to FDAAdvisoryCommittee.com]...
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS042408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel